SCHEMBL2888366

SCHEMBL2888366

N#CSc1ncnc2nc[nH]c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.67
HSD17B10 Q99714 2/20 0.62
TP53 P04637 1/20 0.62
CDC7 O00311 9/20 0.55
DBF4 Q9UBU7 9/20 0.55
PAK1 Q13153 1/20 0.51
TSHR P16473 1/20 0.50
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
HIF1A Q16665 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
PI4KA P42356 2/20 0.48
PI4K2B Q8TCG2 2/20 0.48
PI4K2A Q9BTU6 2/20 0.48
PI4KB Q9UBF8 2/20 0.48
DRD3 P35462 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31606731 0.80 G6PD (1.00) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL2888994 0.80 G6PD (1.00) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL1884553 0.77 G6PD (0.71) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL28322010 0.77 G6PD (0.71) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL240980 0.77 HSD17B10 (1.00) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL30132912 0.77 HSD17B10 (1.00) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL2891519 0.76 MAP3K5 (0.64) HSD17B10TP53HIF1ACYP1A2CYP3A4
SCHEMBL10840233 0.76 HSD17B10 (0.96) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL10840236 0.76 HSD17B10 (0.96) G6PDHSD17B10TP53CDC7DBF4
SCHEMBL1607122 0.73 PI4KA (0.52) G6PDHSD17B10TP53CDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286084-A1 Oligomer-Nucleoside Phosphate Conjugates NEKTAR THERAPEUTICS (US) 2010-11-11 US claimed
WO-2009042064-A2 OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-04-02 WO claimed
US-9365604-B2 Oligomer-nucleoside phosphate conjugates NEKTAR THERAPEUTICS (US) 2016-06-14 US disclosed
US-20140371168-A1 OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES NEKTAR THERAPEUTICS (US) 2014-12-18 US disclosed
US-8741858-B2 Oligomer-nucleoside phosphate conjugates NEKTAR THERAPEUTICS 2014-06-03 US disclosed
US-20100286084-A1 Oligomer-Nucleoside Phosphate Conjugates NEKTAR THERAPEUTICS (US) 2010-11-11 US disclosed
WO-2009042064-A2 OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371168-A1 OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES ENTPD5, SLC29A2, SLC29A1 G6PD 1540/4885HSD17B10 4590/4885TP53 828/4885
US-20100286084-A1 Oligomer-Nucleoside Phosphate Conjugates ENTPD5, SLC29A2, SLC29A1 G6PD 1461/4885HSD17B10 4537/4885TP53 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.